Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor [PDF]
Clinical Journal of the American Society of Nephrology, 2019 Current hemodialysis techniques fail to efficiently remove the protein-bound uremic toxins p-cresyl sulfate and indoxyl sulfate due to their high degree of albumin binding. Ibuprofen, which shares the same primary albumin binding site with p-cresyl sulfate and indoxyl sulfate, can be infused during hemodialysis to displace these toxins, thereby ...
Magdalena, Madero +9 more
openaire +2 more sources
Toxins, 2017 Patients with chronic kidney disease (CKD) have an increased risk of vascular disease, which is associated with considerable health care costs. Vascular disease in CKD differs clinically and pathobiologically from that in patients with normal renal ...
Chih-Cheng Wu +3 more
doaj +1 more source
Toxins, 2021 Cardiorenal syndrome (CRS) is described as primary dysfunction in the heart culminating in renal injury or vice versa. CRS can be classified into five groups, and uremic toxin (UT) accumulation is observed in all types of CRS. Protein-bound uremic toxin (
Carolina Amaral Bueno Azevedo +7 more
doaj +1 more source
Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry : a pilot study [PDF]
, 2017 A typical characteristic of chronic kidney disease (CKD) is the progressive loss in renal function over a period of months or years with the concomitant accumulation of uremic retention solutes in the body.
Boelaert, Jente +5 more
core +1 more source
Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients. [PDF]
, 2016 Dialysis patients display a high cardiovascular mortality, the causes of which are still not completely explained, but are related to uremic toxicity.
Amoresano, A +10 more
core +1 more source
Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
ToxinsCardiovascular disease (CVD) frequently occurs in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The mechanisms behind this may be related to traditional risk factors and CKD-specific factors that accelerate ...
Takuya Wakamatsu +3 more
doaj +1 more source
Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
Toxins, 2018 Cardiovascular disease (CVD) is highly prevalent in the setting of chronic kidney disease (CKD). Such coexistence of CVD and CKD—the so-called “cardiorenal or renocardiac syndrome”—contributes to exponentially increased risk of ...
Suree Lekawanvijit
doaj +1 more source
The uremic toxin indoxyl sulphate enhances macrophage response to LPS. [PDF]
PLoS ONE, 2013 Indoxyl sulphate (IS) is a protein-bound uremic toxin that results from the metabolism of dietary tryptophan normally excreted by kidney through the proximal tubules.
Simona Adesso +6 more
doaj +1 more source
Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway
Toxins, 2021 Activation of mTORC1 (mechanistic target of rapamycin complex 1) in renal tissue has been reported in chronic kidney disease (CKD)-induced renal fibrosis.
Takehiro Nakano +10 more
doaj +1 more source
Thrombotic microangiopathy and associated renal disorders [PDF]
, 2012 Thrombotic microangiopathy (TMA) is a pathological process involving thrombocytopenia, microangiopathic haemolytic anaemia and microvascular occlusion.
Barbour, T +3 more
core +1 more source